Author Archives: admin


Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

FLORHAM PARK, N.J., May 24, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the “Company”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that on May 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Form 10-Q for the quarter ended March 31, 2024 (“Q1 2024 Form 10-Q”), and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended December 31, 2023 (“2023 Form 10-K”), does not comply with the Nasdaq continued listing requirements which require listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. Nasdaq’s notice has no immediate effect on the listing of Celularity’s common stock and warrants, which continue to trade on the Nasdaq Capital Market under the symbols “CELU” and “CELUW”, respectively.

Read more:
Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically…

Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure14,15.

Read more:
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company’s IgA nephropathy (IgAN) portfolio

Basel, May 25, 2024 – Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN)1. Patients treated with atrasentan, in addition to supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor), achieved a 36.1% (p<0.0001) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 36 weeks when compared to placebo on top of supportive care1. The results were presented during a late-breaking clinical trials session at the European Renal Association (ERA) Congress1. The study also showed atrasentan has a favorable safety profile consistent with previously reported data1,9.

Read the original here:
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio

MVP Says He’s Getting Stem Cell Therapy, Wants To Wrestle ‘A Bit More’ Before He Retires – Yahoo Entertainment

MVP provides an update on his status and says he wants to wrestle a bit more before he retires.

In a post on Instagram, MVP revealed that he will be getting stem cell therapy in Mexico. He stated that he wanted to wrestle a bit more before he retires.

Im getting ready for my stem cell therapy trip to Mexico, MVP said. Getting my body ready. I want to wrestle a bit more before I hang them up for good!

In a video in the post, MVP said that he was two weeks out from making the trip. He noted that he was beat up, but he was looking forward to what would happen on the other side. The veteran stated that he had not officially retired yet, and he felt like he needed a few more matches before he hung up his boots.

MVP, a former WWE United States Champion, has not wrestled since 2022. He has mostly worked as a manager in recent years.

WrestleZone will provide more information as it becomes available.

RELATED: MVP Confirms He Hasnt Retired Yet

The post MVP Says Hes Getting Stem Cell Therapy, Wants To Wrestle A Bit More Before He Retires appeared first on Wrestlezone.

Read the original post:
MVP Says He's Getting Stem Cell Therapy, Wants To Wrestle 'A Bit More' Before He Retires - Yahoo Entertainment

Aspen wins grant to advance stem cell therapy for Parkinson’s disease – Parkinson’s News Today

Aspen Neuroscience has been awarded an $8 million grant to advance the clinical development of ANPD001, its investigational stem cell therapy thats designed to replace dopamine-producing nerve cells lost in Parkinsons disease.

The grant, funded by the California Institute for Regenerative Medicine (CIRM), will support the ongoing Phase 1/2a clinical trial thats evaluating the treatment in people with Parkinsons disease. The trial is assessing the use of patients own cells.

Providing patients in this study with dopamine neurons made from their own cells is a huge leap forward for personalized medicine, and has the potential to impact the entire field of neurodegenerative disorders, Damien McDevitt, PhD, Aspens president and CEO, said in a company press release.

This clinical award represents a significant step forward in the treatment landscape of Parkinsons disease by advancing individualized therapy, which has the potential to restore motor function in patients impacted by this devastating condition, said Abla Creasey, PhD, vice president of therapeutics development at CIRM.

Parkinsons is caused by the progressive dysfunction and death of neurons that produce dopamine, a major brain chemical messenger, in the nigrostriatal pathway, which includes the substantia nigra and the dorsal striatum, brain regions involved in motor control.

By the time of diagnosis, it is common for people with Parkinsons to have lost the majority of dopaminergic (DA) neurons, leading to progressive loss of motor and neurological function, said Edward Wirth III, MD, PhD, chief medical officer at Aspen.

ANPD001 uses induced pluripotent stem cells (iPSCs), a type of stem cell that can generate nearly all types of cells in the body, including dopamine-producing neurons. The process involves collecting skin cells from a patient and reprogramming them in the lab as iPSCs.

After iPSCs differentiate into dopamine neuronal precursor cells using specific chemical or biological molecules, they are transplanted back to the patient, where they eventually mature into dopamine-producing neurons.

The main goal of the Phase 1/2a ASPIRO trial (NCT06344026) is to evaluate the long-term safety and tolerability of ANPD001 when transplanted at two escalating doses in people with moderate to severe Parkinsons, ages 50-70.

Secondary goals include increased on time, that is, periods when patients symptoms are well controlled by medication, reduced motor symptoms, and improvement in patients quality of life. Cell survival after the transplant will also be assessed, using imaging brain scans.

The study has completed enrollment, with the patients having been invited by the researchers in advance. The first patient was transplanted last month at the Banner-University Medical Center Tucson and patients will continue to be dosed this year, Wirth said.

The primary follow-up of the trial a year after the transplant should be completed next year and the treatments effects will be assessed for five years after the transplant. Long-term safety data will be evaluated annually for 10 more years via phone call.

Continue reading here:
Aspen wins grant to advance stem cell therapy for Parkinson's disease - Parkinson's News Today

Frederick biotech Theradaptive secures $1M in funding from MD Stem Cell Research Fund for human clinical trials – Maryland Daily Record

Theradaptive Inc., a regenerative medicine company developing targeted therapeutics, Wednesday was awarded $1 million from the Maryland Stem Cell Research Fund (MSCRF) to support human clinical trials for its lead product, OsteoAdapt SP.

OsteoAdapt SP is currently in Phase I/II clinical studies for transforaminal lumbar interbody spinal fusion (TLIF) to treat degenerative disc disease, spondylolisthesis, and retrolisthesis.

Theradaptive was granted an Investigational Device Exemption (IDE) inJanuary by the U.S. Food and Drug Administration (FDA) to begin its human clinical trial. The award from the MSCRF Clinical Program will enable Theradaptive to expand its OASIS human clinical study to sites inMaryland.

OsteoAdapt SP is a biologic-enhanced implant designed to stimulate anatomically precise local bone growth and promote rapid fusion following spinal surgery. It combines a proprietary protein called AMP2 that activates a patients own stem cells with a resorbable scaffold implant.

This implant remodels into bone and completely resorbs, leaving no trace behind. This technology ushers in the next generation of regenerative therapeutics compared to the current standard of care by mitigating side effects and significantly improving safety and efficacy over traditional bone grafts and biologics.

The company was spun out of theMassachusetts Institute of Technologyin 2017 to commercialize a platform that immobilizes therapeutic proteins on implantable biomaterials. The companys near-term focus is on regenerative treatments for musculoskeletal conditions and spinal fusion surgery.

Clinical sites investigating OsteoAdapt SP in TLIF procedures are currently enrolling patients in Maryland and across the United States and inAustralia.

Theradaptive plans to file for marketing authorization with the U.S. Food and Drug Administration following successful completion of pivotal clinical studies.

View post:
Frederick biotech Theradaptive secures $1M in funding from MD Stem Cell Research Fund for human clinical trials - Maryland Daily Record

Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human … – OrthoSpineNews

FREDERICK, Md.,May 22, 2024/PRNewswire/ Theradaptive, Inc., a regenerative medicine company developing targeted therapeutics, announced today it has been awarded funding from the Maryland Stem Cell Research Fund (MSCRF) to support human clinical trials for its lead product, OsteoAdapt SP. OsteoAdapt SP is currently in Phase I/II clinical studies for transforaminal lumbar interbody spinal fusion (TLIF) to treat degenerative disc disease, spondylolisthesis, and retrolisthesis.

Theradaptive was granted an Investigational Device Exemption (IDE) inJanuary 2024by the U.S. Food and Drug Administration (FDA) to begin its human clinical trial. This$1 millionaward from the MSCRF Clinical Program will enable Theradaptive to expand its OASIS human clinical study to sites inMaryland. More details can be found at ClinicalTrials.gov: identifierNCT06154005. Theradaptive also holds three Breakthrough Medical Device designations for various spine indications including TLIF, ALIF, and PLF.

We are so grateful to the Maryland Stem Cell Research Fund for this generous support as we take OsteoAdapt SP through clinical development,saidLuis Alvarez, PhD, CEO and Founder of Theradaptive. This grant will expand our ability to provide patients with limited options a much better alternative by accelerating the development of this ground-breaking technology.

How OsteoAdapt SP is changing biologic implants

OsteoAdapt SP is a biologic-enhanced implant designed to stimulate anatomically precise local bone growth and promote rapid fusion following spinal surgery. It combines a proprietary protein called AMP2 that activates a patients own stem cells with a resorbable scaffold implant. This implant remodels into bone and completely resorbs, leaving no trace behind. This technology ushers in the next generation of regenerative therapeutics compared to the current standard of care by mitigating side effects and significantly improving safety and efficacy over traditional bone grafts and biologics.

This funding will benefit us greatly as we work toward making this revolutionary therapy available to patients in need, puttingMarylandat the forefront of innovation in regenerative bone repairsaidJonathan Elsner, PhD, Vice President of Clinical Operations. We appreciate that MSCRF recognizes the importance of this program and look forward to dosing the first patient in the coming months.

Our goal is to accelerate the development of promising technologies by providing funding to help them reach patients as quickly as possible,said Ruchika Nijhara, Executive Director of MSCRF.We are enthusiastic about the potential of OsteoAdapt SP to benefit patients suffering from debilitating spine conditions.

Theradaptive was spun out of theMassachusetts Institute of Technologyin 2017 to commercialize a platform that immobilizes therapeutic proteins on implantable biomaterials. The companys near-term focus is on regenerative treatments for musculoskeletal conditions and spinal fusion surgery.

Clinical sites investigating OsteoAdapt SP in TLIF procedures are currently enrolling patients across the U.S., includingMaryland, and inAustralia.

Theradaptive plans to file for marketing authorization with the U.S. Food and Drug Administration following successful completion of pivotal clinical studies.

About Theradaptive

Theradaptive, Inc. is a privately held regenerative medicine company developing therapeutic implants that harness the bodys own stem cells to regenerate tissues. The companys proprietary AMP2 technology platform enables localized, sustained delivery of therapeutic proteins to trigger highly targeted regenerative responses.

Theradaptives lead clinical program, OsteoAdapt SP, is an investigational bone graft material designed to improve spinal fusion outcomes. For more information, visitwww.theradaptive.com.

Contact:Harry Warne Senior Contributor Flame PR Harry@flamepr.com

SOURCE Theradaptive

See the rest here:
Theradaptive Secures Landmark Funding from Maryland Stem Cell Research Fund (MSCRF) to Support Human ... - OrthoSpineNews

Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine’s Potential – Intelligent Living

We use technologies like cookies to store and/or access device information. We do this to improve browsing experience and to show (non-) personalised ads. Consenting to these technologies will allow us to process data such as browsing behaviour or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Originally posted here:
Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine's Potential - Intelligent Living

Stem cell therapy success in early trial to treat Parkinson’s disease | PET – BioNews

A stem cell-based therapy for Parkinson's disease entered higher dose clinical testing after a positive initial safety evaluation.

STEM-PD uses human pluripotent stem cells that have been programmed to develop into dopamine nerve cells, which produce a chemical called dopamine that helps to control body movement. The stem cells are then transplanted into the brains of Parkinson's disease patients to replace cells that are lost during the course of the disease and to repair the damage caused. Current drugs, such as levodopa, only temporarily replace dopamine, but do not target the underlying disease.

'The vision is that it could be given as a one-time treatment and the hope is that the patients can reduce their medication, avoid side effects of the drug treatment and get a long-term good motor effect from the cells for life," Dr Gesine Paul-Visse, principal investigator from Lund University and Skne University Hospital, both in Sweden, said.

The method of growing transplantable dopamine cells from stem cells was initially developed by scientists at Lund University. The trial is now a collaboration between Lund University, Skne University Hospital, the University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, and Imperial College London.

The human pluripotent stem cells used for generating the STEM-PD product are obtained from human embryonic stem cells, grown in the laboratory from a surplus embryo from IVF. The cells are then transplanted into a specific area of the patient's brain that is involved in motor control. After a few months, they start sending out nerve fibres and producing dopamine.

STEM-PD has already been shown to be safe and effective at reverting motor deficits in animal models of Parkinson's disease, and entered a first-in-human clinical trial in February 2023 at Skne University Hospital (see BioNews 1164).

An initial four patients were injected with a lower dose of seven million cells, with the team reporting no concerning side effects from the therapy. Furthermore, imaging of the patient brains 6-12 months' post transplantation showed signs of dopamine cell survival. Yet, the team cautions that it is still too early to evaluate the clinical effects of the transplanted stem cells.

The first patient to receive the stem cell therapy a year ago, Thomas Matsson, was diagnosed with Parkinson's disease when he was 42. He can now move freely again and has regained his sense of smell: 'I've reduced my medication for Parkinson's. Before, everything was slow and everything was difficult I do long-distance skating, slalom, cross-country skiing, padel tennis, and, above all, golf,' he said.

Now, a further patient has been injected with a higher dose of 14 million cells, with a further three patients to be treated in 2024. The primary objective of this trial is to assess the safety and tolerability of the therapy after one year, however, the patients will be monitored for three years with a secondary objective to evaluate the clinical efficacy of the therapy.

'There is absolutely hope. Absolutely there is!', added Dr Paul-Visse.

See the rest here:
Stem cell therapy success in early trial to treat Parkinson's disease | PET - BioNews

How to help the public navigate stem cell products – Baylor College of Medicine Blog Network – Baylor College of Medicine | BCM

Society is aging. According to the U.S. Census Bureau, the number of Americans 65 and older is projected to increase from 58 million in 2022 to 82 million by 2050 (a 47% increase), and the 65-and-older age groups share of the total population is projected to rise from 17% to 23%.

As this transition occurs, more and more people will struggle with aches and pains. The frequency of pain in community-dwelling older adults is reported to be as high as 73%. This pain can be related to acute situations (illness and falls) or chronic conditions (arthritis, long-term outcomes from sports injuries, etc.). Regardless of the cause of pain, more and more individuals are seeking non-opioid and non-medicinal approaches to pain management. Current approaches include yoga, exercise, acupuncture, diet changes and, interestingly, stem cell therapy.

For pain sufferers, promising treatments for joint pain and arthritis derived from their own blood or adipose tissue seem miraculous. Such treatments with stem cells are becoming increasingly possible. Pluripotent stem cells are capable of self-renewing and can differentiate into specialized cell types such as blood, bone, cartilage, muscle and even organs.

While there are some legitimate clinical trials to determine if stem cells can help decrease pain or even help repair damaged tissue, there are currently no FDA-approved stem cell products for arthritis or joint pain. Without FDA approval, these products arent known to be safe or efficacious.

For desperate pain sufferers, this can mean that they seek treatment with unapproved and unproven stem cell products. Unfortunately, patients frequently obtain such products through direct-to-consumer advertising. Unapproved and unproven products can be expensive (for example, the average cost is $3,000 $5,000 per injection per knee). They can also be dangerous, not only causing possible local damage but also potentially transmitting infections and diseases.

Unfortunately, pain isnt the only indication for which these clinics and providers use direct-to-consumer advertising to motivate the public to try their unapproved and unproven stem cell products. The products are being used for many other indications, including cosmetic procedures, heart disease, glaucoma and dementia.

The FDA has tried diligently to control the spread of these unethical stem cell clinics through both regulatory actions and direct public education. However, some patients have already been injured by these unapproved and unproven products.

One of the best ways that healthcare providers can help combat the use of unapproved and unproven stem cell therapies is by providing truthful information to patients.

The International Society for Cell and Gene Therapy (ISCT) published a guide for healthcare providers to help them as they educate their patients about stem cells. The guide was developed to help identify and distinguish safe and approved cell and gene therapy products from those that do not have a proven record of safety and efficacy.

As we navigate the complex world of stem cell therapy, its crucial to stay informed and empowered. If you or a loved one are considering stem cell therapy, dont hesitate to consult with a healthcare provider who prioritizes safety and adheres to guidelines set forth by reputable organizations like ISCT. Together, lets ensure that our journey toward medical advancements is as safe as it is promising.

By Bambi Grilley, RPh, RAC, CIP, CCRC, CCRP, Director, Clinical Research and Early Product Development in the Center for Cell and Gene Therapy and professor of Pediatrics at Baylor College of Medicine

See the article here:
How to help the public navigate stem cell products - Baylor College of Medicine Blog Network - Baylor College of Medicine | BCM